"We have synthesized, characterized and in vitro and in vivo tested new biodegradable carrier systems for long lasting circulation in the blood stream useful\u00A0in a different experimental model of cancer. New reactive polymeric precursors, copolymers of N-("@en . . . "Polymeric cytostatics"@en . "http://www.isvav.cz/projectDetail.do?rowId=GA305/02/1425"^^ . . "GA305/02/1425" . . "1"^^ . "Conventional chemotherapy exposes both normal and neoplastic cells to identical doses of cytotoxic agents. Therapeutic efficacy could be enhanced and non-specific toxicity greatly diminished if the cytotoxic drug is conjugated to a macromolecular carrier. We have documented the advantages of water-soluble copolymer carrier (PHPMA)-bound drugs, targeted or nontargeted, compared to free drugs. Among these advantages are long-lasting circulation in the bloostream, decreased immunogenicity and non-specific toxicity, increased active accumulation at the tumor site by targeting and passive accumulation by KPR effect, the ability to overcome P-glycoprotein dependent MDR, immunoprotecting and immunomoblizing activities. The most successful material we have designed so far has been based on a non-biodegradable poly (HPMA) copolymer carrier to which drug and a targeting moiety were conjugated through biodegrdable oligopeptide side chains. The aim of this project is to design new"@en . . "Neuvedeno."@en . . "Polymern\u00ED cytostatika" . "1"^^ . "2008-06-02+02:00"^^ . "Konven\u010Dn\u00ED chemoterapie vystavuje norm\u00E1ln\u00ED i n\u00E1dorov\u00E9 bu\u0148ky identick\u00E9 d\u00E1vce l\u00E9\u010Diva. Zv\u00FD\u0161it terapeutickou \u00FA\u010Dinnost a sou\u010Dasn\u011B sn\u00ED\u017Eit nespecifickou toxicitu lze doc\u00EDlit t\u00EDm, \u017Ee l\u00E9\u010Divo je nav\u00E1z\u00E1no na makromolekul\u00E1rn\u00ED nosi\u010D. V\u00FDhod, kter\u00E9 maj\u00ED l\u00E9\u010Diva nav\u00E1zan\u00E1 na vodorozpustn\u00FD nosi\u010D PHPMA, a\u0165 u\u017E sm\u011Brovan\u00FD nebo nesm\u011Brovan\u00FD, p\u0159i srovn\u00E1n\u00ED s l\u00E9\u010Divy nemodifikovan\u00FDmi je cel\u00E1 \u0159ada. Pat\u0159\u00ED mezi n\u011B dlouhodob\u00E1 cirkulace v krvi, sn\u00ED\u017Een\u00E1 imunogenicita a nespecifick\u00E1 toxicita, zv\u00FD\u0161en\u00E1 aktivn\u00ED akumulace v n\u00E1doru zp\u016Fsoben\u00E1 sm\u011Brov\u00E1n\u00EDm a pasivn\u00ED akumulace dan\u00E1 EPR efektem, schopnost p\u0159ekonat na Pgp-dependentn\u00ED MDR, imunoprotek\u010Dn\u00ED a imunomobiliza\u010Dn\u00ED vlastnosti. N\u00E1\u0161 dosud nej\u00FAsp\u011B\u0161n\u011Bj\u0161\u00ED polymern\u00ED nosi\u010D byl nebiodegradovateln\u00FD poly(HPMA), na kter\u00FD bylo jak l\u00E9\u010Divo, tak i sm\u011Bruj\u00EDc\u00ED struktura, nav\u00E1z\u00E1ny pomoc\u00ED biodegradovateln\u00FDch oligopeptidick\u00FDch spojek. C\u00EDlem p\u0159edkl\u00E1dan\u00E9ho projektu je vyvinout nov\u00E9 biodegradovateln\u00E9 nosi\u010Dov\u00E9 syst\u00E9my, umo\u017E\u0148uj\u00EDc\u00ED dlouhodobou cirkulaci v krvi a vyu\u017Eiteln\u00E9 pro terapii kolorekt\u00E1ln\u00EDho" . . . . "62"^^ . "62"^^ . . . "0"^^ . . . . . . "Byly p\u0159ipraveny, charakterizov\u00E1ny a otestov\u00E1ny jak in vitro tak in vivo nov\u00E9 biodegradovateln\u00E9 nosi\u010Dov\u00E9 syst\u00E9my, umo\u017E\u0148uj\u00EDc\u00ED dlouhodobou cirkulaci v krvi a vyu\u017Eiteln\u00E9 pro r\u016Fzn\u00E9 modelov\u00E9 n\u00E1dorov\u00E9 syst\u00E9my. Nov\u011B byly syntetizov\u00E1ny a fyzik\u00E1ln\u011B-chemicky charak"@cs . . . . . .